A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Fixed Dose, Clinical Trial of Quetiapine 600 mg/Day vs 1200 mg/Day for Patients With Treatment-Resistant Schizophrenia or Schizoaffective Disorder

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Apr 2015

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 28 Jul 2011 Planned End Date changed from 1 Mar 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top